FLORIANA DE CILLIS

Dr. FLORIANA DE CILLIS

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
FCFLORIANA DE CILLIS
FLORIANA DE CILLIS
VBVeronica Begni
Veronica Begni
PGPatrizia Genini
Patrizia Genini
DLDaniele Leo
Daniele Leo
Marco Andrea RivaMarco Andrea Riva
Marco Andrea Riva
ACAnnamaria Cattaneo
Annamaria Cattaneo
Major depressive disorder (MDD) is a complex, multifactorial condition involving dysregulation across immune, neural, and metabolic systems. Omega-3 polyunsaturated fatty acids (n-3 PUFAs), particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have emerged as promising adjunctive interventions, with evidence supporting their efficacy in alleviating depressive symptoms. Here, we synthesize current knowledge on the interconnected biological pathways through which n-3 PUFAs may exert antidepressant effects. A growing body of evidence implicates the gut–brain axis as a central pathway through which n-3 PUFAs may exert antidepressant effects. By shaping microbiota composition and metabolite production, n-3 PUFAs influence intestinal permeability, immune activation, and vagal signaling, thereby contributing to both immunomodulatory and neurochemical effects. In combination, n-3 PUFAs modulate peripheral and central inflammation by promoting specialized pro-resolving mediators, downregulating pro-inflammatory cytokines, and influencing microglial activation. Parallel actions on neuronal membrane composition and lipid raft integrity affect neurotransmitter signaling, synaptic plasticity, and neurogenesis, with downstream effects on neural function. Additional pathways, including hypothalamic–pituitary–adrenal axis regulation and oxidative stress reduction, further integrate n-3 PUFA actions across multiple systems. Collectively, these mechanisms suggest that n-3 PUFAs act as network modulators, supporting recovery in depression. Translational research highlights the importance of EPA-predominant formulations, optimal dosing, and patient stratification. By framing n-3 PUFAs activity within a multi-level systems biology perspective, this review provides a comprehensive mechanistic understanding and underscores their potential as targeted adjunctive strategies for MDD.

16 September 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
VMVeronica Mutti
Veronica Mutti
GCGiulia Carini
Giulia Carini
MMMoira Marizzoni
Moira Marizzoni
AFAlice Filippini
Alice Filippini
FBFederica Bono
Federica Bono
IRIsabella Russo
Isabella Russo
Chronic neuroinflammation plays a crucial role in the progression of neurodegenerative diseases (NDs), including Parkinson’s disease (PD) and Alzheimer’s disease (AD). Leucine-Rich Repeat Kinase 2 (LRRK2), a gene linked to familial and sporadic PD, has been positively associated with neuroinflammation in both in vitro and in vivo systems. These observations suggest that LRRK2 might actively contribute to neuronal damage and degeneration in NDs. Based on these premises, we explored the impact of LRRK2-mediated neuroinflammation on neurons in a PD- and AD-related context. We set up a cellular model composed of human induced pluripotent stem cell (hiPSC)-derived neurons (dopaminergic for PD and cholinergic for AD) exposed to inflamed glial medium [α-synuclein pre-formed fibrils (α-syn pffs) for PD and amyloid-β (Aβ)1–42 fibrils for AD] for several days. To dissect the effect of neuroinflammation, and specifically, the role of LRRK2, on neuronal functions, we first performed transcriptome analysis, and then, we validated the results at functional levels. Interestingly, we found that LRRK2-dependent neuroinflammation contributes to neuronal dysfunctions and death in both ND contexts and that LRRK2 kinase inhibition prevents these detrimental effects. Overall, our results suggest that lowering neuroinflammation through LRRK2 pharmacological inhibition might limit the progression of NDs and thus be neuroprotective.

8 May 2021 in Cancers
Verified
Journal Article
Open access
PDF file
RRRoberto Ronca
Roberto Ronca
STSara Taranto
Sara Taranto
MCMichela Corsini
Michela Corsini
CTChiara Tobia
Chiara Tobia
CRCosetta Ravelli
Cosetta Ravelli
Arianna GiacominiArianna Giacomini
Arianna Giacomini
During multiple myeloma (MM) progression the activation of the angiogenic process represents a key step for the formation of the vascular niche, where different stromal components and neoplastic cells collaborate and foster tumor growth. Among the different pro-angiogenic players, Fibroblast Growth Factor 2 (FGF2) plays a pivotal role in BM vascularization occurring during MM progression. Long Pentraxin 3 (PTX3), a natural FGF antagonist, is able to reduce the activation of stromal components promoted by FGF2 in various in vitro models. An increased FGF/PTX3 ratio has also been found to occur during MM evolution, suggesting that restoring the “physiological” FGF/PTX3 ratio in plasma cells and BM stromal cells (BMSCs) might impact MM. In this work, taking advantage of PTX3-inducible human MM models, we show that PTX3 produced by tumor cells is able to restore a balanced FGF/PTX3 ratio sufficient to prevent the activation of the FGF/FGFR system in endothelial cells and to reduce the angiogenic capacity of MM cells in different in vivo models. As a result of this anti-angiogenic activity, PTX3 overexpression causes a significant reduction of the tumor burden in both subcutaneously grafted and systemic MM models. These data pave the way for the exploitation of PTX3-derived anti-angiogenic approaches in MM.

29 August 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
FCFLORIANA DE CILLIS
FLORIANA DE CILLIS
GPGiulia Petrillo
Giulia Petrillo
IDIlari D’Aprile
Ilari D’Aprile
MMMoira Marizzoni
Moira Marizzoni
SSSaleri Samantha
Saleri Samantha
ACAnnamaria Cattaneo
Annamaria Cattaneo
Background: The gut microbiota and the gut epithelium play a central role in maintaining systemic and brain homeostasis from early life. Stressful experiences during sensitive developmental windows can disrupt this balance, increasing long-term susceptibility to psychiatric disorders. However, the mechanisms through which early-life alterations in the microbiota influence brain development and function remain poorly understood. Here, the sex-specific impact of prenatal stress (PNS) on gut integrity and microbial composition in adult offspring was explored. Methods: Thirty dams were mated and randomly assigned to PNS or control. Offspring microbiota was analysed through 16S rRNA sequencing, intestinal morphology with morphometric analyses, and tight junctions using qPCR and immunofluorescence. Results: Exposure to PNS was associated with reduced intestinal surface area in males and shortened crypts in females. In both sexes, PNS caused a decrease in the expression of ZO-1, suggesting impaired gut barrier integrity. 16S rRNA sequencing revealed, furthermore, that PNS exposure was associated with a decrease in beneficial genera, including Akkermansia in males and Clostridia vadinBB60 in females, along with an increase in the pro-inflammatory genus Anaerotruncus, regardless of sex. Notably, some of these alterations were more pronounced in PNS-exposed animals that showed impaired sociability, highlighting gut microbiota inter-individual variability in the response to early-life adversity. Moreover, selected microbial changes show significant correlations with the behavioural outcomes, as well as with intestinal morphology or brain inflammatory markers. Conclusions: Together, these findings pinpoint the gut as a central player in stress vulnerability and highlight specific microbial signatures as promising biomarkers and therapeutic targets for stress-related disorders.

24 March 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
VBVeronica Begni
Veronica Begni
FCFLORIANA DE CILLIS
FLORIANA DE CILLIS
NPNatascha Pfeiffer
Natascha Pfeiffer
STSteven R. Talbot
Steven R. Talbot
PGPeter Gass
Peter Gass
AMAnne Stephanie Mallien
Anne Stephanie Mallien
Pharmacological antidepressant treatments alter the molecular and functional reactivity of stress-sensitive neural networks. However, how classical versus rapid-acting antidepressants differentially modulate acute stress-induced transcriptional responses across brain regions remains unclear. Here, we compared imipramine and ketamine in mice exposed to acute swim stress, assessing transcriptional adaptations across the frontal cortex, hippocampus, and striatum. Swim stress induced significant widespread activation of cFOS, which led to drug-specific modulations: imipramine primarily significantly dampened cortical and striatal cFOS expression, whereas ketamine preserved stress-evoked neuronal activation. In contrast, hippocampal activation was significantly robust but largely unaffected, indicating that acute antidepressant drug effects during stress coping preferentially target cortical and striatal plasticity mechanisms. In contrast, BDNF expression was altered only within the striatal region, where imipramine attenuated the stress-related increase in BDNF expression. Statistical analysis of behavioral outcomes during the swim stress confirmed a shared facilitation of active coping, yet these similar outcomes emerged from distinct molecular programs. Together, the data demonstrate that the treatment effects of the two substances diverge mechanistically, revealing cortical and striatal transcriptional signatures of classical versus rapid-acting antidepressant action. While these findings suggest potential translational relevance for understanding distinct mechanisms, further studies in humans are required to validate these signatures and their clinical implications.

2 October 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
TPTiziano Prodi
Tiziano Prodi
MNMaria Gabriela Nielsen
Maria Gabriela Nielsen
FCFLORIANA DE CILLIS
FLORIANA DE CILLIS
NCNadia Cattane
Nadia Cattane
MMMoira Marizzoni
Moira Marizzoni
ACAnnamaria Cattaneo
Annamaria Cattaneo
Interindividual variability in psychotropic drug response contributes to treatment failure, adverse drug reactions, and repeated medication adjustments. Pharmacogenetics supports precision prescribing by identifying genetic variants associated with drug metabolism, efficacy, and tolerability, and evidence-based recommendations are available for several psychotropic medications. However, genotype predicts metabolic capacity rather than the enzyme activity actually expressed in vivo or the systemic drug exposure achieved at a given time. This narrative review examines phenoconversion, the mismatch between genotype-predicted and observed metabolic phenotype, and its implications for psychiatric pharmacotherapy. Drug–drug interactions, smoking, inflammation, physiological changes, and disease-related factors can modify drug-metabolizing enzyme activity or otherwise alter systemic drug exposure despite an unchanged genotype. We discuss how these influences can limit the applicability of genotype-based dosing recommendations and propose a dynamic framework integrating pharmacogenetic results with concomitant medications, clinical conditions, lifestyle factors, therapeutic drug monitoring, and longitudinal changes in patient status. This framework may also refine the assessment of treatment adequacy, because prescribed dose, duration, and adherence do not necessarily ensure adequate drug exposure. Future clinical decision-support systems should combine pharmacogenetic and longitudinal clinical data to enable more individualized and dynamically informed psychopharmacological treatment.